Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
NCT ID: NCT04795596
Last Updated: 2022-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2/PHASE3
INTERVENTIONAL
2021-04-01
2022-04-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer
NCT00006356
Primary Cyto-reductive Surgery Vs Neo-adjuvant Chemotherapy (NAC) in Epithelial Ovarian Cancer
NCT04257786
IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer
NCT01588964
Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval
NCT00657878
Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer
NCT05633199
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
surgery + chemotherapy
surgical resection for recurrent platinum resistant ovarian cancer followed by second line chemotherapy as per the investigator's choice
secondary cytoreductive surgery
resection of isolated recurrent ovarian carcinoma in platinum resistant disease
Chemotherapy
second line chemotherapy according to investigator's choice
chemotherapy alone
second line chemotherapy according to investigator's choice
Chemotherapy
second line chemotherapy according to investigator's choice
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
secondary cytoreductive surgery
resection of isolated recurrent ovarian carcinoma in platinum resistant disease
Chemotherapy
second line chemotherapy according to investigator's choice
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* amenable to complete gross resection, isolated recurrence
* adequate renal, hepatic, and bone marrow function,
* performance-status ECOG score of 0 to 2.
Exclusion Criteria
* diffuse carcinomatosis, ascites, or extra-abdominal disease
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Menoufia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Sohaib
Principal investigator, Lecturer of Clinical oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Menoufia University, Faculty of medicine
Shibīn al Kawm, Menoufia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626.
Du Bois A, Vergote I, Ferron G et al. A randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 2017; 35(Suppl): abstr #5501
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
388
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.